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Piper sarmentosum is a tropical plant in Southeast Asia known for its traditional use in curing various ailments including
hypertension. Previous research works have provided evidence for the herb’s antihypertensive property. However, the exact
mechanisms involved are still in question. ,e present study investigated the effects of Piper sarmentosum leaves aqueous extract
(PSAE) treatment on vascular endothelin system in spontaneously hypertensive rats (SHRs). Four groups of SHRs were treated for
28 consecutive days, with negative and positive control groups receiving distilled water and 3mg/kg perindopril, respectively.
Another two groups are the treatment groups, which received PSAE and combination of 1.5mg/kg perindopril and PSAE.Weekly
measurements of blood pressure showed that PSAE significantly reduced the systolic, diastolic, and mean arterial pressures
(P< 0.05) of the rats. PSAE also increased mesenteric artery nitric oxide (NO) level (P< 0.05) and reduced endothelin-1 (ET-1)
level (P< 0.05) in the treatment groups. Our results demonstrate that oral administration of PSAE reduced blood pressure in SHRs
by reducing the ET-1 level while increasing NO production.
1. Introduction
Hypertension remains a health burden worldwide as it is one
of the key risk factors for cardiovascular diseases, the biggest
contributors of global mortality [1]. Being the leading
preventable cause of premature death worldwide, the at-
tention hypertension got over the past decades until today is
plethoric. However, despite established studies of antihy-
pertensive medications, substantial hurdles still remain in
overcoming the disease [2–4]. One major factor that con-
tributes to this problem is the complexity of the disease itself.
,e pathophysiology of hypertension involves de trop in-
terplay between renal, neural, cardiovascular, and endocrine
factors modulated by genetic and environmental factors.
,is complex polygenic disorder occurs as a result of ad-
ditive effects of multiple variant genes working en masse and
in concert with the necessary environmental conditions to
elevate blood pressure [5–9].
One of the mechanisms responsible for elevated blood
pressure in hypertension is the impairment of endothelial
physiological function, otherwise known as endothelial
dysfunction [10–12]. Endothelial dysfunction is character-
ized by an imbalance between endothelial-derived vaso-
dilating and vasoconstricting factors which are nitric oxide
(NO) and endothelin-1 (ET-1), respectively, by which the
former is downregulated and vice versa [13]. Failure of the
physiological balance between these two molecules breaks
down the homeostasis of the vascular beds, abetting the
pathological process of the vascular diseases. ,is imbalance
occurs via reduced NO synthesis, reduced NO bio-
availability, or antagonism of NO by endothelium-derived
contracting factors such as ET-1 [12].
ET-1 is one of the three endothelins expressed in
humans, secreted by endothelial cells in blood vessels and in
many other cells of the body. ,is main endothelin is a
potent vasoconstrictor [14] and, via ETA receptor activation,
Hindawi
Evidence-Based Complementary and Alternative Medicine
Volume 2019, Article ID 7198592, 8 pages
https://doi.org/10.1155/2019/7198592
causes various actions in the kidney. When administered on
a long-term basis, it results in an increase of blood pressure
and contributes to the development of hypertension [15]. It
also stimulates oxidative stress by causing upregulation of
the nicotinamide adenosine dinucleotide phosphate
(NADPH) oxidase subunits, increasing superoxide [16].
,ese characteristics of ET-1 make it a key regulator in
hypertension and a biomarker for endothelial dysfunction.
Piper sarmentosum Roxburgh (Piperacea) is a herba-
ceous plant familiar in the Southeast Asian region. It has
long been used traditionally as a herbal medicine to treat
diabetes, hypertension, and joint aches [17], toothache,
coughing, pleurisy, fever, headache [18], feet dermatomy-
coses, and indigestion [19]. Extensive studies have been done
for its pharmacological activities such as antihypertensive
[20, 21], anti-inflammatory [22, 23], antiatherosclerosis
[24, 25], antiangiogenic [26], hypoglycemic [27], antifungal
[28, 29], antibacterial [30, 31], and antiprotozoa [32]. ,is
plant also exhibits high antioxidant property [17, 33, 34].,e
high antioxidant activity exhibited by this plant helps to
balance reactive oxygen species (ROS) formation, thus al-
leviating endothelial oxidative stress, increasing NO bio-
availability in human umbilical vein endothelial cells
(HUVECs) [34].
Recent study with PSAE showed that administration of
the extract lowers blood pressure in SHRs, affecting diastolic
blood pressure (DBP) more than systolic blood pressure
(SBP) [20]. Supplementation with Piper sarmentosum in this
study also demonstrated an increased NO level in SHRs,
promoting vascular relaxation. However, whether endo-
thelin system is involved in the mechanism is still yet to be
determined. Furthermore, although involvement of re-
sistance artery in blood pressure regulation is pivotal, there
is no report about the effect PSAE has on them. In the
present study, we investigated the efficacy of PSAE in
maintaining vascular endothelin system homeostasis as one
of the mechanisms responsible for lowering blood pressure
in SHRs.
2. Materials and Methods
2.1. Plant Material. Fresh PS leaves were collected from a
thicket in Kuantan, Pahang, Malaysia (GPS coordinate:
3.8098666979082325, 103.31667760157472), on 10th and
11th of October 2016 at 9.30 to 11.30 in the morning. ,e
specimen sample was authenticated by Dr. Shamsul Khamis,
a botanist at the National University of Malaysia (UKM)
Bangi Herbarium, and deposited in the Herbarium, Kul-
liyyah of Pharmacy, IIUM Kuantan, Malaysia (voucher
specimen number: PPIUM 0239-2 [VS-4]).
2.2. Preparation of Piper sarmentosum Leaves Aqueous
Extract. Fresh Piper sarmentosum leaves were washed
thoroughly with tap water and then cut and dried under
shade at ambient temperature for three days.,e leaves were
then further dried in an oven at 40°C for four hours until
they became brittle. ,e dried leaves were triturated until
they turned into coarse powder and kept in hermetically
sealed jars at 4°C until further processing. ,e powdered dry
leaves were then extracted at the General Laboratory of
Central Research and Animal Facility (CREAM), Kulliyyah
of Science, IIUM, Kuantan in Pahang, Malaysia. An amount
of 100 grams of the powdered leaves were added to 900ml of
distilled water and heated at 80°C for three hours. ,e
concentrated plant extract was then cooled and filtered,
before lyophilised by a freeze-drier. Finally, the powdered
form extract was stored at 4°C until use.
2.3. Experimental Animals. Male SHRs aged 11weeks old
with initial 250± 10% g body weight obtained from Animal
Research and Service Centre (ARASC), University of Science
Malaysia (USM) Kubang Kerian, Kelantan, Malaysia, were
used in this study.,e rats were kept singly in polypropylene
cages under standard laboratory conditions of 24± 4°C
temperature, with relative humidity of 55± 10%, in 12 hour
light dark cycle. Adequate cross ventilation was provided,
and they were given standard commercial dry pellet (Gold
Coin Sdn. Bhd.) and distilled water ad libitum.
After one week acclimatization with weight increment,
a total of 24 SHRs were randomly and equally divided into
four groups: negative control group which received an
amount of vehicle (distilled water) according to PSAE dose,
not exceeding 2ml/100 g body weight/day; positive control
group which received 3mg/kg/day perindopril (Servier
Malaysia Sdn. Bhd); PSAE group which received 500mg/kg
PSAE; and PSAE + perindopril group which received
500mg/kg PSAE and 1.5mg/kg/day perindopril. Baseline
blood pressure was measured and recorded before treat-
ment was started. Treatment was given for 28 consecutive
days. ,e formulated dose of PSAE and period of treatment
were based on studies by Mohd Zainudin et al. [20]. ,e
treatment materials were prepared into solutions before-
hand and were administered intragastrically via oral ga-
vage. ,e rats’ blood pressure was measured weekly during
the treatment period. On day 29, the rats were dissected,
and mesenteric arteries were harvested. ,e samples were
analysed for determination of the vascular ET-1 and NO
levels. All procedures were conducted in accordance with
animal ethics and protocol from the guidelines of the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals [35] and approved by IIUM In-
stitutional Animal Care and Use Comitte (IACUC-IIUM),
Malaysia, with the approval number IIUM/IACUC Ap-
proval/2016/(11)(72).
2.4. Determination of Blood Pressure and Heart Rate. ,e
rats’ blood pressure (BP) was measured in the morning
between 8 and 11 am weekly after 22–24 hours of admin-
istration of vehicle or treatment substances. ,ey were
measured in conscious, prewarmed, and restrained rats
using the noninvasive technique by a plethysmographic tail-
cuff method by the CODA™ noninvasive blood pressure
(NIBP) system (Kent Scientific Corporation, USA). ,irteen
determinations were made in every session of BP mea-
surement, and the mean of three values within 15mmHg
was taken as the BP level.
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2.5.Dissection andPreparation ofMesenteric Artery. ,e rats
were anaesthetized intravenously with Ketamine +
Xylazine +Zoletil® (KTX) cocktail and dissected. ,e entiresmall intestinal mesenteric bed, still attached to the small
intestines, was then harvested and submerged into ice-cold
PBS. ,e SHRs were then euthanized by cardiac removal.
Gentle blunt dissection was done on the mesenteric arcade
to remove nerve bundles, connective tissues, mesenteric
vein, and adherent fat from the mesenteric artery on bone
wax-coated Petri dish on ice (Figure 1). Finally, the cleaned
mesenteric artery was snap-frozen in liquid nitrogen and
kept at −80°C until further analysis.
2.6. NO Measurement. Mesenteric artery NO level was
determined by measuring nitrite (NO2−) concentration
using QuantiChrom™ Nitric Oxide Assay Kit (D2NO–100)
obtained from i-DNA Biotechnology Sdn Bhd, Malaysia.
,e kit applies colorimetric assay according to the improved
Griess method.
2.7. ET-1 Measurement. ,e concentration of ET-1 in
mesenteric artery was determined using a rat ET-1 ELISA kit
(Elabscience®, USA).
2.8. Statistical Analysis. Results were expressed as mean-± standard error of mean (SEM). A one-way repeated
measures analysis of variance (ANOVA) was run to compare
mean blood pressure between study groups during treat-
ment period while Bonferroni post hoc test was performed
to test the significance of mean difference between the
groups. Meanwhile, the statistical mean difference of NO
and ET-1 level between the four study groups were com-
pared by one-way ANOVA with subsequent post hoc
Tukey’s HSD test. P-values of less than 0.05 were considered
to be statistically significant.
3. Results
3.1. PSAE Reduces Blood Pressure but Not Heart Rate
in SHRs. After the treatment was started, all of the treated
groups displayed significantly lower (P< 0.05) mean SBP,
DBP, and MAP as compared to the negative control group.
However, among the treated groups, PSAE-treated rats
showed significantly higher mean SBP, DBP, and MAP
compared to rats in the PSAE+ perindopril-treated group
and positive control group. In the meantime, no significant
differences of mean SBP, DBP, and MAP were observed
between the PSAE+ perindopril combination-treated group
and the positive control group (Figures 2–4).
In this study, mean heart rate of all groups demonstrated
inconsistent values throughout the study period. ,ere was
no statistically significant difference (P< 0.05) in the heart
rate recorded among all of the groups during treatment
period (Figure 5).
3.2. Effects of PSAE on NO Level in Mesenteric Arteries. In
present study, SHRs administered with PSAE, PSAE+
perindopril, and perindopril orally for 28days had a signifi-
cantly higher (P< 0.05) NO level in the mesenteric arteries as
compared to the untreated group. ,e PSAE-treated group
showed the lowestmeanNO level among the treatment groups.
However, there was no significant difference of mean NO level
between the PSAE-treated group with both positive control
group and the PSAE+perindopril-treated group (Figure 6).
3.3. Effects of PSAE on ET-1 Level in Mesenteric Arteries.
Both groups receiving PSAE and PSAE+perindopril, as well
as the positive control group, recorded significantly
(P< 0.05) lower mesenteric arteries ET-1 concentration than
the negative control group. Among the treatment groups,
mean ET-1 concentration was highest in the group receiving
PSAE. Nevertheless, there was no statistically significant
difference of mean ET-1 level between the PSAE-treated
group with both the positive control group and
PSAE+perindopril-treated group (Figure 7).
4. Discussion
Endothelium is a squamous, single-cell lining membrane
covering the inner wall of vessels. Once thought to only
function as a barrier separating the circulating blood and
vascular smooth muscle cells (VSMC), endothelium is now
considered as having an important role in modulating
vascular function. Endothelial cells synthesize and release a
number of essential factors that are involved in maintaining
the homeostatic balance of blood vessels. Any imbalance of
these mediators’ bioavailability leads to vascular diseases
such as hypertension [36]. Two of the mediators are NO and
endothelin. ,ese two mediators have a close relationship in
maintaining the balance in endothelial functions in which
the disequilibrium will cause endothelial dysfunction [37].
Endothelial dysfunction, which refers to an impairment
in its vasodilatory capacity, plays a crucial role in patho-
genesis of hypertension [12]. ,e characteristic imbalance
between endothelium-dependent vasodilation and vasocon-
striction in endothelial dysfunction occurs through reduced
NO synthesis, reduced NO bioavailability, or antagonism of
NO by endothelium-derived contracting factors. One of the
causes that can reduce synthesis of NO is decreased endo-
thelial nitric oxide synthase (eNOS) activity caused by
competitive inhibition of eNOS by asymmetric dimethy-
larginine (ADMA).Meanwhile, reduced bioavailability of NO
can be caused by reactive oxygen species (ROS) which convert
NO to peroxynitrite [12, 38]. Diminished NO bioavailability
caused by the oxidative stress causes unabated actions of ET-1
leading to vasoconstriction and vascular remodelling,
resulting in increased blood pressure. Results from our study
provide more evidence of antihypertensive property of PSAE
and the mechanisms that may be responsible. Oral admin-
istration of PSAE reduces blood pressure and may improve
resistance arteries endothelial function by increasing NO
bioavailability, thus decreasing ET-1 in SHRs.
SHRs are known to display many characteristics of the
human essential hypertension [39]. ,e increase in blood
pressure and peripheral resistance in SHRs is preceded by
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vascular oxidative stress, which results in endothelial dys-
function [40]. Reduction of blood pressure in our study may
partly be caused by debilitation of the endothelial dys-
function present in the animals.
Apart from having a role as a potent vasoconstrictor, ET-
1 also upregulates NADPH oxidase (NOX) subunits, which
are a major source of ROS in the cardiovascular system.
,us, ET-1 increases superoxide anion, stimulating oxida-
tive stress [41]. However, ET-1 pathway is antagonized by
NO through reduction of the preproendothelin-1 (ppET-1)
mRNA via downregulation of ppET-1 gene transcription
and through endothelial cGMP-dependent mechanism
[42, 43]. NO also decreases the duration of interaction
between ET-1 and its receptors, as well as inhibiting ET-1
signaling at the VSMC calcium signaling level [44].
Accordingly, an increased NO level will mitigate ET-1
actions and thus rehabilitate endothelial function. On the
other hand, a decrease in the NO level, which occurs
during hypertension, will pathologically lead to an in-
creased ET-1 level, causing endothelial dysfunction. ,e
action of NO in antagonizing ET-1 is proven by the
present study, in which the levels of ET-1 in the resistance
vessels of the rats in the treated groups were significantly
lower than that in the negative control group. Meanwhile,
the NO levels of the same mesenteric arteries in the PSAE-
(a) (b) (c)
Figure 1: Images of mesenteric vessels under dissecting microscope. (a) Before removal of connective tissues and nerve bundle
with (i) artery, (ii) vein, and (iii) adhering fat visible. (b) After removal of most connective tissue and nerve bundle. (i) ,e artery located
under (ii) the veins appeared “whiter” than the latter. (c) ,e cleaned arteries.
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Figure 2: Weekly evolution of systolic blood pressure obtained by
the tail-cuff method. Negative control�nontreated SHRs. Positive
control� SHRs treated with perindopril. Values are expressed as
mean± SEM with n� 6. #Significant mean difference with negative
control group (P< 0.05); ∗significant mean difference with both
positive control and PSAE+ perindopril combination group
(P< 0.05).
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Figure 3: Weekly evolution of diastolic blood pressure obtained by
the tail-cuff method. Values are expressed as mean± SEM with
n� 6. Negative control� nontreated SHRs. Positive control� SHRs
treated with perindopril. #Significant mean difference with negative
control group (P< 0.05); ∗significant mean difference with both
positive control and PSAE+ perindopril combination group
(P< 0.05).
4 Evidence-Based Complementary and Alternative Medicine
treated and PSAE + perindopril-treated rats were signif-
icantly higher as compared to the negative control group.
e eect was comparable to the rats in positive control
group, which were treated by perindopril, a long-acting
angiotensin converting enzyme (ACE) inhibitor. is
drug works on renin-angiotensin-aldosterone system
(RAAS) by inhibiting ACE, which is responsible for
converting angiotensin I into angiotensin II (ANG II), a
potent vasoconstrictor. ANG II also stimulates vaso-
pressin and aldosterone secretion which increase water
and sodium retention. ese actions of ANG II increase
both preload and afterload, subsequently increasing blood
pressure [45].
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Figure 4: Weekly evolution of mean arterial pressure obtained by
the tail-cu method. Values are expressed as mean± SEM with
n 6. Negative controlnontreated SHRs. Positive control SHRs
treated with perindopril. #Signicant mean dierence with negative
control group (P< 0.05); ∗signicant mean dierence with both
positive control and PSAE+ perindopril combination group
(P< 0.05).
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Figure 5: Mean of SHRs heart rate obtained by the tail-cu
method. Values are expressed as mean± SEM with n 6. Negative
controlnontreated SHRs. Positive control SHRs treated with
perindopril.
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Figure 6: Eect of PSAE and PSAE+ perindopril combination
on the nitric oxide (NO) level of spontaneously hypertensive rat
(SHR). Values are expressed as mean± SEM (P< 0.05), with
n 6. APSAE-treated group, B PSAE+ perindopril-treated
group. Negative control untreated SHRs, Positive con-
trol perindopril-treated SHRs. #Signicant mean dierence
with negative control group (P< 0.05).
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Figure 7: Eect of PSAE and PSAE+ perindopril combination on
the endothelin-1 (ET-1) level of spontaneously hypertensive rat
(SHR). Values are expressed as mean± SEM (P< 0.05), with n 6.
Negative control untreated SHRs, Positive control perindopril-
treated SHRs. #Signicant mean dierence with negative control
group (P< 0.05).
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Reduction of endothelial NO bioavailability is closely
associated with an overall increase in ROS [46, 47], which
may explain the reason why the mechanism of endothelial
dysfunction which contributes to hypertension is also
strongly related with oxidative stress. Hence, the ability of
PSAE in increasing NO bioavailability may be caused by its
capacity of maintaining the redox balance resulting from its
rich antioxidant content.
Furthermore, several chemical constituents in Piper
sarmentosum (PS) such as naringenin [17], quercetin [48],
sesamin [49], rutin, and vitexin [50] have been reported to
protect blood vessels and might be able to convalesce vas-
cular injury. Quercetin, a flavonoid compound, has been
proven to exhibit cardioprotective effects in prehypertensive
men and women by improving endothelial function and
reducing inflammation [51]. It is able to improve endothelial
function by preventing ET-1-induced vascular superoxide
anion production. ,is action is accomplished by reduction
of p47phox overexpression, thus reducing subsequent in-
creased NOX activity and uncoupled eNOS [52]. A study by
Loke et al. in 2008 suggested that quercetin and epicatechin
can acutely improve endothelial function by modulating the
circulating concentrations of NO and ET-1 which was
possibly exerted through inhibition of NOX and activation
of eNOS [53]. Another flavonoid in PS, vitexin, possesses
antihypertensive property by causing relaxation of vascular
contraction regardless of endothelial function, by inhibiting
phorbol ester-induced increases in pERK1/2 levels [54].
Vitexin has also been reported to be a hypotensive com-
pound by having diuretic effects attributed to the inhibition
of sodium-chloride-symporter system in the renal distal
tubule, instead of having direct vasodilation effect [55].
Rutin, which is also one of the flavonoids in PS may improve
endothelial function by augmenting NO production through
inducement of eNOS gene expression, protein synthesis, and
activity in oxidative stress-induced HUVEC [49]. Another
chemical constituent contained in PS, sesamin, was reported
to induce NO and inhibit endothelin converting enzyme
(ECE) gene expression through NO signaling. Sesamin also
acts as an antioxidant, decreasing ROS and inducing NOS
gene expression [56]. However, further studies are needed to
determine whether the antihypertensive effect of PSAE is
due to their original composition and the synergistic action
of several antioxidant compounds contained in the plant or
due to a unique active compound.
On the other hand, for blood pressure, our study found that
PSAE did reduce blood pressure but showed no superior effect
as compared to perindopril. ,e rats treated with combination
of half dose of perindopril and PSAE however displayed lower
blood pressure during treatment period comparable to those
receiving full dose of perindopril. Nonetheless, whether the
effect had been solely contributed by addition of PSAE needs
further investigation. ,e dose of perindopril used in the
combination therapy during this study was halved to in-
vestigate the effect of PSAE cotreatment with a lowered
treatment dose of conventional therapy. Optimizing drug
dosage permits the benefits of minimizing drug wastage in-
cidence and increasing compliance, holding potential for en-
hancing therapeutic outcomes while concomitantly decreasing
the incidence of adverse drug events, as well as reducing patient
healthcare cost [57].
Although the exact mechanism(s) regarding how PSAE
lowers blood pressure is not fully understood yet, results
from our study suggested that attenuation of vascular en-
dothelial dysfunction due to NO bioavailability augmenta-
tion might be substantially responsible. ,is is evident when
perindopril, which works on RAAS, lowered blood pressure
more than PSAE did while the same rats of all treated groups
had statistically comparable ET-1 andNO levels at the end of
the study. Such inference is plausible considering the
complexity of essential hypertension pathogenesis that in-
volves interaction of multiple organ systems and various
mechanisms.
5. Conclusions
,is study demonstrated that the antihypertensive effect of
orally administered PSAE in SHRs may be due to its ability
to ameliorate endothelial dysfunction by increasing the
resistance artery NO level and reducing the resistance artery
ET-1 level. ,e effect may be attributed to high antioxidant
property of the plant, thoughmore thorough study is needed
to prove it. ,is present study also showed that the effects of
PSAE given once daily may not be superior to those of full-
dose perindopril. ,us, a further study that analyses a “bis in
die” (BD) dose of PSAE on the SHRs is needed to elucidate
whether PSAE has a comparable antihypertensive effect to a
full-dose perindopril. Further study by combining the plant
extract with full dose of perindopril is also needed to
evaluate whether the plant addition exerts more beneficial
effects or not. ,is will confirm the plant synergistic effect
with perindopril and its ability as adjunctive treatment. In
addition, meta-analysis trials with large sample size and
excellent methodological qualities will help to provide a
confirmed conclusion of the effectiveness and safety of PSAE
as adjunctive treatment for essential hypertension. Finally, a
study on long-term effect of prolonged PSAE ingestion, as
well as a clinical study, will also be needed in order for PSAE
to be used in humans.
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